MediWound's EscharEx Phase III Trial Cleared to Proceed Without Changes
Event summary
- Independent DSMB recommended continuation of MediWound’s Phase III VALUE study for EscharEx without modification.
- No safety concerns identified in the pre-specified safety review.
- Interim sample-size reassessment and enrollment completion expected by Q1 2027.
- VALUE trial aims to enroll 216 patients across 40 sites in the U.S., Europe, and Israel.
- EscharEx is a bromelain-based enzymatic therapy for chronic wound debridement.
The big picture
MediWound’s EscharEx represents a next-generation enzymatic therapeutic aimed at transforming chronic wound management. The DSMB’s recommendation to continue the Phase III trial without modification underscores the therapy’s favorable safety profile and positions it as a potential disruptor in the wound care market. The successful completion of the VALUE study could pave the way for broader applications in diabetic foot ulcers and pressure ulcers, further expanding MediWound’s market reach.
What we're watching
- Clinical Execution
- Whether MediWound can maintain the current pace of enrollment and meet the Q1 2027 deadline for the VALUE study.
- Regulatory Pathway
- How the favorable DSMB recommendation impacts the likelihood of EscharEx's eventual approval for venous leg ulcers.
- Market Opportunity
- The potential expansion of EscharEx into other chronic wound indications, such as diabetic foot ulcers and pressure ulcers.
Related topics